Lafunomyl (Alfuzosin Hydrochloride)

Alfuzosin selectively blocks alpha‑1 adrenergic receptors in the prostate, bladder neck and urethra. By preventing norepinephrine‑mediated muscle contraction, it relaxes the smooth muscle of the urinary outflow tract, decreasing obstruction and allowing urine to pass more freely.

The dose of Lafunomyl is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and concomitant medications. Physicians typically start with a standard daily dose and may adjust it as needed, but the exact regimen should always follow the prescriber’s instructions.

Safety data for alfuzosin during pregnancy and lactation are limited. The product is generally not recommended for use in pregnant or nursing women unless the potential benefit justifies the potential risk, and such decisions should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Lafunomyl product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The most common alternative to alfuzosin is tamsulosin, another selective alpha‑1 blocker. Both improve urinary flow, but alfuzosin has a slightly longer half‑life and may cause fewer sexual side effects such as retrograde ejaculation. Choice of therapy depends on individual patient response, tolerability and physician preference.

Lafunomyl tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original container, protect it from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

Lafunomyl is taken orally, usually once daily with or without food, as directed by the prescribing physician. Swallow the tablet whole with a full glass of water and follow any specific timing instructions provided by the healthcare professional.

The most serious adverse events linked to alfuzosin include severe hypotension, syncope, priapism, and rare cardiac arrhythmias such as prolonged QT interval. Patients should be monitored for signs of low blood pressure, chest discomfort, or abnormal heart rhythms, and seek immediate medical attention if these occur.

Lafunomyl is contraindicated in patients with known hypersensitivity to alfuzosin or any component of the formulation. It should also be avoided in individuals taking concomitant alpha‑blockers, nitrates, or potent CYP3A4 inhibitors without medical supervision, as well as in patients with severe hepatic impairment unless dose adjustments are made.